Paper25901475
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Sakamoto K and 10 others. Int J Oncol, 2015. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA. Papers, record 25901475. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25901475
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimetabolites, Antineoplastic | Major topic |
| Colorectal Neoplasms | Major topic |
| DNA, Neoplasm | Major topic |
| Fluorouracil | Major topic |
| Thymidine Kinase | Major topic |
| Trifluridine | Major topic |
| Uracil | Major topic |
| Drug Combinations | |
| Equilibrative Nucleoside Transporter 1 | |
| Equilibrative-Nucleoside Transporter 2 | |
| HCT116 Cells | |
| Humans | |
| Male | |
| Pyrophosphatases | |
| Pyrrolidines | |
| Substrate Specificity | |
| Thymine |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2971045 | Isolation and characterization of a mutant of L1210 murine leukemia deficient in nitrobenzylthioinosine-insensitive nucleoside transport. | J Biol Chem | 1988 | https://conductscience.org/library/papers/2971045 | PubMed |
| 2 | 285077 | Human deoxyuridine triphosphate nucleotidohydrolase. Purification and characterization of the deoxyuridine triphosphate nucleotidohydrolase from acute lymphocytic leukemia. | J Biol Chem | 1979 | https://conductscience.org/library/papers/285077 | PubMed |
| 3 | 6305486 | Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. | Cancer Res | 1983 | https://conductscience.org/library/papers/6305486 | PubMed |
| 4 | 7999767 | Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2'-deoxyuridine 5'-monophosphate. | Biochemistry | 1994 | https://conductscience.org/library/papers/7999767 | PubMed |
| 5 | 7494863 | Mammalian deoxyribonucleoside kinases. | Pharmacol Ther | 1995 | https://conductscience.org/library/papers/7494863 | PubMed |
| 6 | 9771948 | Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. | Cancer Chemother Pharmacol | 1998 | https://conductscience.org/library/papers/9771948 | PubMed |
| 8 | 14186018 | SYNTHESES OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE. | J Med Chem | 1964 | https://conductscience.org/library/papers/14186018 | PubMed |
| 9 | 15571283 | Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. | Nucleosides Nucleotides Nucleic Acids | 2004 | https://conductscience.org/library/papers/15571283 | PubMed |
| 10 | 15711180 | Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. | Anticancer Drugs | 2005 | https://conductscience.org/library/papers/15711180 | PubMed |
| 11 | 17441963 | Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. | Cancer Sci | 2007 | https://conductscience.org/library/papers/17441963 | PubMed |
| 12 | 20372850 | Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. | Oncol Rep | 2010 | https://conductscience.org/library/papers/20372850 | PubMed |
| 13 | 20371715 | Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. | Mol Cancer Ther | 2010 | https://conductscience.org/library/papers/20371715 | PubMed |
| 14 | 19417150 | XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. | Mol Cancer Ther | 2009 | https://conductscience.org/library/papers/19417150 | PubMed |
| 15 | 21319870 | Treatment of viral conjunctivitis with antiviral drugs. | Drugs | 2011 | https://conductscience.org/library/papers/21319870 | PubMed |
| 16 | 20560137 | Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. | Int J Cancer | 2011 | https://conductscience.org/library/papers/20560137 | PubMed |
| 17 | 22068047 | Thymidine kinase and cancer monitoring. | Cancer Lett | 2012 | https://conductscience.org/library/papers/22068047 | PubMed |
| 18 | 22172489 | Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22172489 | PubMed |
| 19 | 22951287 | TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22951287 | PubMed |
| 20 | 23604282 | Heterogeneity of tumor-induced gene expression changes in the human metabolic network. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/23604282 | PubMed |
| 21 | 25230742 | Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. | Oncol Rep | 2014 | https://conductscience.org/library/papers/25230742 | PubMed |
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42592050 | Nucleotide Metabolism in Health and Disease. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42592050 | PubMed |
| 42168481 | Trifluridine/tipiracil enhances radiation-induced abscopal effects and augments PD-1 blockade in gastric cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/42168481 | PubMed |
| 40807411 | Incorporation and Repair of Epigenetic Intermediates as Potential Chemotherapy Agents. | Molecules | 2025 | https://conductscience.org/library/papers/40807411 | PubMed |
| 40673011 | Total neoadjuvant therapy integrating long-course radiotherapy with trifluridine/tipiracil for locally advanced rectal cancer: a single-arm, multicenter phase 2 trial. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/40673011 | PubMed |
| 40358665 | Impact of renal function on non-hematologic toxicities in mCRC patients treated with TAS-102: a post-hoc analysis of the JASCC-CINV2001 study. | Support Care Cancer | 2025 | https://conductscience.org/library/papers/40358665 | PubMed |
| 39747494 | Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab. | Sci Rep | 2025 | https://conductscience.org/library/papers/39747494 | PubMed |
| 39244627 | TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. | Br J Cancer | 2024 | https://conductscience.org/library/papers/39244627 | PubMed |
| 38630197 | The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study. | Support Care Cancer | 2024 | https://conductscience.org/library/papers/38630197 | PubMed |
| 38202064 | A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer. | J Clin Med | 2023 | https://conductscience.org/library/papers/38202064 | PubMed |
| 37940878 | Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37940878 | PubMed |
| 36291880 | External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36291880 | PubMed |
| 35599264 | A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. | Med Oncol | 2022 | https://conductscience.org/library/papers/35599264 | PubMed |
| 35280098 | Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report. | Clin Case Rep | 2022 | https://conductscience.org/library/papers/35280098 | PubMed |
| 34884270 | Biomarkers of Trifluridine-Tipiracil Efficacy. | J Clin Med | 2021 | https://conductscience.org/library/papers/34884270 | PubMed |
| 33895696 | Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. | ESMO Open | 2021 | https://conductscience.org/library/papers/33895696 | PubMed |
| 33780084 | Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment. | Cancer Sci | 2021 | https://conductscience.org/library/papers/33780084 | PubMed |
| 32457882 | β-Elemene Reverses the Resistance of p53-Deficient Colorectal Cancer Cells to 5-Fluorouracil by Inducing Pro-death Autophagy and Cyclin D3-Dependent Cycle Arrest. | Front Bioeng Biotechnol | 2020 | https://conductscience.org/library/papers/32457882 | PubMed |
| 32322913 | Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. | Cancer Chemother Pharmacol | 2020 | https://conductscience.org/library/papers/32322913 | PubMed |
| 32162797 | Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. | Oncologist | 2020 | https://conductscience.org/library/papers/32162797 | PubMed |
| 31619711 | CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure. | Sci Rep | 2019 | https://conductscience.org/library/papers/31619711 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DUT | 1854 | PubTator's text mining | https://conductscience.org/library/genes/1854 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| POLA1 | 5422 | PubTator's text mining | https://conductscience.org/library/genes/5422 | NCBI Gene |
| SLC29A1 | 2030 | PubTator's text mining | https://conductscience.org/library/genes/2030 | NCBI Gene |
| SLC29A2 | 3177 | PubTator's text mining | https://conductscience.org/library/genes/3177 | NCBI Gene |
| TDG | 6996 | PubTator's text mining | https://conductscience.org/library/genes/6996 | NCBI Gene |
| TK1 | 7083 | PubTator's text mining | https://conductscience.org/library/genes/7083 | NCBI Gene |
| TK2 | 7084 | PubTator's text mining | https://conductscience.org/library/genes/7084 | NCBI Gene |
| TYMP | 1890 | PubTator's text mining | https://conductscience.org/library/genes/1890 | NCBI Gene |
| TYMS | 7298 | PubTator's text mining | https://conductscience.org/library/genes/7298 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25901475
GET https://conductscience.org/api/papers/v1/25901475/references?page=2